Discover investment opportunities in Pharma Stocks List using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharma Stocks List using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Pharma Stocks List using our Smart AI Filter.
10 stocks found for "Pharma Stocks List"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.22 Risk measure | ±27.3% Price volatility | 15.0 Valuation | 2.83% Annual yield | |||
0.32 Risk measure | ±24.8% Price volatility | 8.7 Valuation | 6.75% Annual yield | |||
0.33 Risk measure | ±27.9% Price volatility | 8.6 Valuation | 4.00% Annual yield | |||
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.98 Risk measure | ±24.4% Price volatility | 25.1 Valuation | 1.27% Annual yield | |||
0.35 Risk measure | ±28.9% Price volatility | 6.7 Valuation | 5.29% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
0.45 Risk measure | ±25.0% Price volatility | 14.4 Valuation | 3.19% Annual yield | |||
0.37 Risk measure | ±19.7% Price volatility | 14.7 Valuation | 3.18% Annual yield | |||
0.59 Risk measure | ±31.6% Price volatility | 34.5 Valuation | 0.77% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do Pfizer's (PFE) recent drug approvals impact its stock performance?
A: Pfizer's (PFE) recent drug approvals can potentially boost its revenue and stock value as it strengthens its product pipeline. Market acceptance and the ability to meet regulatory requirements will influence long-term impacts. Investors should watch quarterly earnings and sales figures for these new drugs.
Q: What growth prospects does Merck (MRK) offer compared to its competitors?
A: Merck (MRK) has a strong foothold in oncology through its Keytruda treatment, driving significant revenue growth. Its focus on innovation and a robust pipeline positions it competitively in the pharma sector, but investors should compare pipeline advancements and market share with companies like JNJ and LLY.
Q: What dividend potential does Johnson & Johnson (JNJ) have?
A: Johnson & Johnson (JNJ) historically offers a stable dividend yield, benefiting income-focused investors. Its diversified business model across pharmaceuticals, medical devices, and consumer health provides resilience in maintaining payouts. Investors should consider historical payout ratios and dividend growth trends.
Q: How might Novartis (NVS) restructure impact its stock?
A: Novartis's (NVS) ongoing restructuring, focusing on core therapeutic areas and streamlining operations, might enhance profitability but could also introduce short-term volatility. Investors are advised to follow restructuring progress and its impact on operating margins and growth.
Q: What is Eli Lilly's (LLY) strategy for dealing with drug pricing pressures?
A: Eli Lilly (LLY) tackles pricing pressures through value-based pricing models and innovative products like diabetes and oncology solutions. Monitoring policy changes and pricing strategies will be crucial for investors tracking LLY's revenue and market position.
Q: Does Bristol-Myers Squibb (BMY) offer potential for value investing?
A: Bristol-Myers Squibb (BMY) presents opportunities for value investors, offering a competitive P/E ratio in the sector. Its strong oncology pipeline and recent acquisitions enhance growth potential, but risk stems from patent expirations and competition.
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read more